SMi Group's 9th annual ADMET conference & exhibition returns to London at the end of June

1. BOOK BY 31ST MARCH AND SAVE £300
BOOK BY 30TH APRIL AND SAVE £100
“Great conference! Well organised”
Sanofi
30TH JUNE
-1ST JULY
SMi present their 9th annual conference on…
ADMET
Enhancing drug quality by ADMET optimisation
in discovery
2014
The Marriott Regents Park Hotel, London, UK
Conference chairs:
• erry Kenna, Safety Science Adviser and Network Partner,
G
The Research Network
• lan Wilson, Vice President, Lexicon Pharmaceuticals
A
Key Speakers:
• atalie Gobeau, Metabolism and Pharmacokinetics, Novartis
N
• ietmar-Weitz, Lab Head/ADME In Vitro Systems, Sanofi-Aventis
D
• arah Baldwin, In Vitro DMPK Manager, GSK
S
• hris Powell, VP Safety Assessment, GSK
C
• eorg Schmitt, Head of Toxicology, Roche Pharmaceuticals
G
• ichard Thompson, Principal Scientist, AstraZeneca
R
• ranck Atienzar, Associate Director, In Vitro and In Silico Toxicology, UCB
F
• dina Tocoian, Senior Clinical Pharmacologist, UCB
A
• avid Fairman, Senior Clinical Pharmacokinetist, MedImmune
D
WHY ATTEND THIS EVENT:
• Understand how to integrate ADME and toxicity data to enhance the
prediction and understanding of drug safety in humans
• Hear the latest updates on drug transporters including the evolving
transporter strategies in drug development and the different roles of
drug transporters in R&D
• Explore the ADME properties of peptides in drug discovery
• Evaluate and overcome the challenges of making an accurate
human dose prediction
PLUS TWO INTERACTIVE HALF-DAY POST-CONFERENCE WORKSHOPS
Wednesday 2nd July 2014, The Marriott Regents Park Hotel, London, UK
A: Computational Approaches in ADMET
B: ADME for the Medicinal Chemist
Workshop Leader: Dr Nick Plant, Reader in Molecular Toxicology,
University of Surrey
Workshop Leader: Dr Corinne Kay, Company DIrector, Med-Simple
1.30pm - 5.30pm
8.30am - 12.30pm
Sponsored by
www.admet-event.com
Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711
BOOK BY 31ST MARCH AND SAVE £300 • BOOK BY 30TH APRIL AND SAVE £100

2. ADMET 2014
www.admet
Day One I Monday 30th June 2014
8.30
Registration & Coffee
1.00
Networking Lunch
9.00
Chairman’s Opening Remarks
Alan Wilson, Vice President, Lexicon Pharmaceuticals
2.00
Exploring the ADME properties of peptides in drug discovery
• Metabolism of peptides
• What in vitro metabolism studies can we employ?
ADMET IN DRUG DEVELOPMENT
9.10
• LC-MS analysis of peptides in drug discovery
• Absorption of peptides
Role of ADMET in drug development
Jørgen Olsen, Principal Scientist, Novo Nordisk
• Role of ADMET in optimizing drug discovery and
development
• The role of good laboratory practice in non-clinical ADMET
2.40
studies
• Contrasting small and large molecule ADME challenges
• Optimizing the value of predictive ADMET/PK
• Introduction to monoclonal antibody (mAB) PK and PKPD
• Future opportunities and challenges
• mAB half life modification strategies
Alan Wilson, Vice President, Lexicon Pharmaceuticals
9.50
ADME for biologics, progress and challenges
The challenges of making an accurate human dose
prediction
David Fairman, Senior Clinical Pharmacokinetist, MedImmune
3.20
Afternoon Tea
• How to predict accurate PK parameters
PREDICTIVE VALUE OF TOXICITY
• What in vitro and in vivo tools can we use and how should
we use them
• Understanding the driver of efficacy
3.50
The role of non-clinical safety testing in drug research &
• Dealing with active processes
development and clinical safety
• Understanding and appreciation of errors and their
• Non-regulated and regulated areas
implications
• Predictive value with a focus on toxicology
Peter Littlewood, Director DMPK, Vertex
• Strategic approaches within the value chain
• Personal view and outlook
10.30 Session reserved for Corning Life Sciences
Georg Schmitt, Head of Toxicology, Roche Pharmaceuticals
David Stresser, Program Manager, Drug Metabolism Services,
Corning Life Sciences
4.30
11.10 Morning Coffee
• xCELLingence platform (impedance)
• Advantages and drawbacks
11.40 Immunogenicity assessment of monoclonal antibodies and
The use of label free technologies in drug development
• Defining optimal conditions for your cells
bio-technology derived therapeutic proteins
• Toxicity and pharmacology
• Scientific and regulatory considerations on the
CASE
STUDY
• Coupling RTCA with cell imaging
immunogenicity of biologics
Franck Atienzar, Associate Director, UCB
• Comparative review of the EMA vs. FDA guidelines for
immunogenicity of biologics
development
5.10
Contemporary nonclinical approaches to cardiac safety
• A risk based approach to immunogenicity concerns in drug
assessment in drug development
Adina Tocoian, Senior Clinical Pharmacologist, UCB
• Overview of CV data generated in the preclinical space
• Reducing attrition: in silico, in vitro, in vivo assessment
BIOLOGICS V/S SMALL MOLECULES IN ADMET
• Integration of data to inform on pathogenesis
• Building an integrated structure/function strategy to CV
12.20 Modulation of drug absorption via internal hydrogen bonding
safety
• Impact of internal H-bonding on absorption
• Prediction of internal H-bonding
• Application to drug design
Andy McElroy, CEO, EligoChem Ltd
Official Media Partners
Peter Clements, Director of Pathology, GSK
CASE
STUDY
5.50
Chairman’s Closing Remarks and Close of Day One
Supported by
Register online at: www.admet-event.com • Alternatively fax you

3. ADMET 2014
t-event.com
Day Two I Tuesday 1st July 2014
8.30
Registration & Coffee
12.20 Integrating ADME and toxicity data to enhance the prediction
and understanding of drug safety in humans
9.00
Chairman’s Opening Remarks
• ADME endpoints considered most relevant to drug safety
Gerry Kenna, Safety Science Adviser and Network Partner,
• Value and limitations of in vivo toxicity assessment
The Research Network Ltd
• In silico and in vitro toxicity evaluation
• Approaches for data integration – the need for
9.10
physiologically based systems models
Risk assessment and mitigation strategies for reactive
metabolites in drug discovery
Gerry Kenna, Safety Science Adviser and Network Partner,
The Research Network Ltd
• isk factors: drug related and patient related
R
• Risk assessment and mitigation strategies in the
pharmaceutical industry
• Idiosyncratic adverse drug reactions:
CASE
STUDY
Multiple contributory mechanisms
1.00
Networking Lunch
2.00
Significance of plasma protein binding for pharmacokinetics
and the utility of TRANSIL assays
• Case study
• Free fraction and equilibrium distribution
Richard Thompson, Principal Scientist, AstraZeneca
• Binding site affinity, receptor affinity and displacement
• Plasma dilution, apparent recovery are absolute recovery
9.50
Experimental strategies to predict [and therefore avoid]
• Assay systems for peptide drugs
adverse hepatic effects in clinical trials
Hinnerk Boriss, CEO, Sovicell
• Current challenges in predicting clinical hepatotoxicity
UPDATE ON DRUG TRANSPORTERS
• Sensitivity, specificity & clinical relevance of experimental
models
• Differences in the underlying mechanism(s) of hepatic
2.40
Evolving transporter strategies in drug development
• Understanding clinically relevant drug transporters and their
dysfunction
importance in the pharmaceutical industry
• Use of emerging technologies like 3D cell culture to predict
• Case study at GSK
hepatotoxicity
• Drug transporter regulatory interactions
Chris Powell, VP Safety Assessment, GSK
CASE
STUDY
• Key learnings & application to future projects
Sandra Baldwin, In Vitro DMPK Manager, GSK
10.30 Morning Coffee
toxicity
3.20
Afternoon Tea
3.50
11.00 Assessing the effectiveness of non-animal models to predict
In vivo models for the study of drug transporters
• Prediction goals in using computational and in vitro
• nimal models available
A
approaches to assess toxicity
- Knockout and transgenic animals
• Understanding and evaluating the latest models
• elevance and experimental settings
R
• Predicting end points and future challenges and
• ase studies and potential applications
C
Laurent Salphati, Senior Scientist, Genentech
opportunities
Alan Boobis, Professor of Biochemical Pharmacology,
Imperial College London
4.30 The different roles of drug transporters in research and
development
• rug and drug metabolites are actively transported into and
D
IN SILICO AND IN VITRO APPROACHES
out of cells by a variety of transporters
• ransporters – a view from different angles: determinant of
T
11.40 What added value can PBPK bring to drug discovery?
PK, PD, efficacy and safety
• Overview of PBPK
• egulatory guidance, clinical importance and implications
R
• Possible applications in drug discovery
• ow far is ‘IVIVC’ for transporters?
H
• Case studies
Dietmar Weitz, Lab Head/ADME in Vitro Systems, Sanofi-Aventis
• Challenges and opportunities
Nathalie Gobeau, Metabolism and Pharmacokinetics, Novartis
5.10
Chairman’s Closing Remarks and Close of Day Two
Supported by
ur registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711
Want to know how you can
get involved?
Interested in promoting your
services to this market?
Contact Teri Arri,
SMi Marketing on
+44 (0) 207 827 6162 or
email tarri@smi-online.co.uk

4. HALF-DAY POST-CONFERENCE WORKSHOP A
Wednesday 2nd July 2014 I 08.30 – 12.30 I Marriott Regents Park Hotel, London, UK
In association with
Computational Approaches in ADMET
Overview of workshop:
About the workshop host:
Within the last few years there has been a step-change in the use
of computational approaches to examine biological processes. An
important challenge is to use these new approaches to better predict
drug action (both pharmacology and toxicology) as early in the drug
pipeline as possible
Dr Nick Plant has nearly 20 years’ experience researching
the coordination of cellular responses, which balance
the adaptation to altered chemical environments within
the body, while maintaining core body functioning.
His research has focussed on members of the superfamily of nuclear receptors, which act as ligandactivated transcription factors, sensing their cellular surroundings
and coordinating network responses. Utilising both small- and largescale computational approaches his lab aims to understand the
coordination of body responses to both external perturbations (e.g.
dietary and pharmacological) and during disease progression (e.g.
breast cancer), as well as feasibility studies towards the reconstruction
of the “silicon human”.
This workshop will cover both the theory of these new approaches, and
the application of them to a real test case. No previous experience in
computational modelling will be assumed!
Why you should attend:
Computational biology is a rapidly changing field, with new approaches
being developed every day. This workshop will help the non-specialist
understand what they can expect from such approaches, why these
approaches can be applied to ADMET and how they can apply them
to their own projects.
Note: Practical Session presume that attendees will have access to
a PC/tablet and Internet access. Practical Sessions will be run via the
network.
About The University of Surrey
The University of Surrey is a UK top-ten research intensive University
based at Guildford, Surrey, UK. Its computational and Systems biology
research group is based within the Faculty of Health and Medical
Sciences.
Programme:
08.30
09.00
09.10
09.50
10.30
11.00
11.40
12.20
Registration and coffee
Opening remarks
Session 1 Theory of Relational Databases
Session 2 Practical Session on Relational Databases
Coffee break
Session 3 Theory of Constraint-Based Models
Session 4 Practical Session on Constraint-Based Models
Closing remarks
HALF-DAY POST-CONFERENCE WORKSHOP A
Wednesday 2nd July 2014 I 13.30 – 17.30 I Marriott Regents Park Hotel, London, UK
In association with
ADME for the Medicinal Chemist
Overview of workshop:
The session will begin an overview of the digestive system and relate
each organ to its corresponding ADME issue. An interactive workshop
will focus on routes of administration.
A second session will focus on permeability, Pgp and CYP 450 and
will be followed by a workshop where participants will explore the
literature to distil working solutions to recurrent medicinal chemistry
issues.
Why you should attend:
Medicinal chemists with up to 5 years in industry. Academics who wish
to acquaint themselves with key issues in the drug discovery process.
The session is suitable to graduates, PhD and Post Doctoral fellows and
assumes no prior knowledge. This workshop is not suitable for scientists
already versed in ADME.
Programme:
13.30 Registration and coffee
14.00 Opening remarks
14.10 Session 1 ADME – Voyage through the digestive system
14.50 Session 2 Workshop – Routes of dministration & literature
a
abstraction
15.30 Coffee break
16.00 Session 3 Permeability & Pgp
16.30 Session 4 Liver Metabolism
17.20 Closing remarks
17.30 End of workshop
About the workshop hosts:
Corinne read Organic Chemistry at Lyon University, France
(1984). She then joined Roche (1984-1990) as a medicinal
chemist where she was involved in the Trocade as well as
the Saquinavir projects. In addition, she played a key role
in establishing a Solid Phase Peptide and Oligonucleotide
synthesis facility in house. She then Joined Glaxo in 1990,
where she has worked on a number of Protease and GPCR drug
Discovery projects at various stages of lead discovery and lead
optimisation. Corinne then obtained a GlaxoSmithKline sponsored
PhD at the University of Cambridge (2000) having worked with Prof S V
Ley, FRS on the discovery of novel solid phase amine linkers. She then
joined Organon in 2001 where she became responsible for Medicinal
Chemistry training of staff and more recently founded Med-Simple,
a company specialising in applied Medicinal Chemistry training. She
is the author of over 45 publications, book chapters and reviews in
these areas. Her research interests include the design of chemical
libraries, peptide synthesis, solid phase synthesis and ADME.
About the organisation
Med-Simple was created in 2004 and provides tailor-made medicinal
chemistry courses for the pharmaceutical industry. In the spirit of the
company motto is ‘Things should be as simple as they can be’ (A.
Einstein) Med-Simple prides itself in delivering complex medicinal
chemistry concepts in an easy to digest format. Its trademark
‘Succeed through the li terature approach’, as well as innovative
teaching methods have placed the company finalist in the 2012 Small
Business Award for Innovation.

5. Sponsored by
Admescope provides innovative contract research services for preclinical ADMETox, from tailor-made assays to HTS-studies. In addition to having comprehensive
service portfolio in the field, we are specialized in drug metabolism and drug
interaction studies. Currently Admescope serves customers in Europe, USA and
Canada, from virtual biotechs to Big Pharma companies. To learn more, please
visit www.admescope.com
Corning Life Sciences is a global manufacturer of tools and equipment for cell
culture, molecular biology, drug discovery and microbiology. Our leading Corning®,
Falcon®, Costar®and Gosselin™ brands include vessels and differentiated surfaces
for cell culture and scale-up, liquid handling products, ADME/Tox products and
services, microbiology consumables and purification kits.
www.corning.com/lifesciences
SPONSORSHIP AND EXHIBITION OPPORTUNITIES
SMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your
company’s marketing strategy. Prime networking opportunities exist to entertain, enhance and expand your
client base within the context of an independent discussion specific to your industry. Should you wish to join
the increasing number of companies benefiting from sponsoring our conferences please call:
Alia Malick, Director on+44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk
Who should attend this conference:
Previous Attendee Profile
You should attend this event if you are a Chief
Executive, Vice President, Head, Director, Chief
Scientist, Principal Scientist, Project Leader, Manager
from within the Pharmaceutical or Healthcare
industry within responsibilities in the following areas:
Chief Principle Scientist
CEO/Director/Manage
Head of Pharmacology/DMPK/Toxicology
Professor/Academia
Other
• ADME
• Toxicology
• DMPK
• PBPK
• PD/PK
• Computational Modelling and Simulation
• Pathology
• Computational Chemistry
• Computational Toxicology
• Pre-clinical Safety
• Clinical Pharmacology
• Genotoxicity
• Drug Metabolism
• Regulatory Pharmaco-Toxicology
35%
23%
21%
14%
5%
21%
35%
5%
14%
23%
SMi FORWARD PLANNER
MARCH
APRIL
JUNE
Superbugs & Superdrugs - A Focus on
Antibacterials
5 – 6 March 2014, London
Asthma & COPD
BioBanking
23 – 24 June 2014, London
Imaging in Cancer Drug Development
12 – 13 March 2014, London
Controlled Release
12 – 13 March 2014, London
Adaptive Designs
24 – 25 March 2014, London
Paediatric Clinical Trials
31 March – 1 April 2014, London
Pre-Filled Syringes USA
31 March – 1 April 2014, USA
2 – 3 April 2014, London
Biosimilars USA
7 – 8 April 2014, USA
Peptides
30 June – 1 July 2014, London
MAY
ADMET
30 June – 1 July 2014, London
Big Data in Pharma
12 – 13 May 2014, London
JULY
Pain Therapeutics
19 – 20 May 2014, London
Lyophilisation
7 – 8 July 2014, London
ADC Summit
19 – 20 May 2014, London
BioNetworks
7 – 8 July 2014, London
Clinical Trial Logistics
21 – 22 May 2014, London
Allergies
9 – 10 July 2014, London
Immunogenicity
14 – 15 July 2014, London

6. ADMET 2014
Conference: Monday 30th June and Tuesday 1st July 2014 , The Marriott Regents Park Hotel, London, UK I Workshops: Wednesday 2nd July 2014, London
4 WAYS TO REGISTER
ONLINE www.admet-event.com
FAX your booking form to +44 (0) 870 9090 712
PHONE on +44 (0) 870 9090 711
POST your booking form to: Events Team, SMi Group Ltd, 2nd Floor
South, Harling House, 47-51 Great Suffolk Street, London, SE1 0BS, UK
EARLY BIRD □
DISCOUNT □
Book by 31st March to receive £300 off the conference price
Book by 30th April to receive £100 off the conference price
CONFERENCE PRICES
I would like to attend: (Please tick as appropriate) Fee
Unique Reference Number
Our Reference
GROUP DISCOUNTS AVAILABLE
P-109
DELEGATE DETAILS
Please complete fully and clearly in capital letters. Please photocopy for additional delegates.
Title: Forename:
Surname:
Job Title:
□ Conference & 2 Workshops
□ Conference & 1 Workshop
□ Conference only
□ 1 Workshop only
□ 2 Workshops only
Workshop A □ Workshop B □
£2098.00 + VAT £2517.60
£1499.00 + VAT £1798.80
£599.00
Company/Organisation:
Email:
+ VAT £718.80
£1198.00 + VAT £1437.60
PROMOTIONAL LITERATURE DISTRIBUTION
□ Distribution of your company’s promotional
literature to all conference attendees
£999.00
Department/Division:
Total
£2697.00 + VAT £3236.40
+ VAT £1198.80
The Conference fee includes refreshments, lunch, conference papers and
CD ROM containing all of the presentations.
Company VAT Number:
Address:
LIVE STREAMING/ON DEMAND/DOCUMENTATION
Town/City:
Post/Zip Code:
Country:
Direct Tel:
Direct Fax:
Mobile:
Switchboard:
Signature:
Date:
I agree to be bound by SMi’s Terms and Conditions of Booking.
ACCOUNTS DEPT
Title: Forename:
Surname:
Unable to travel, but would like to watch the conference live,
ask questions, participate as if you were in the room?
Price
Total
□ Live Streaming
£999.00 + VAT £1198.80
□ On demand
£599.00 + VAT £718.80
(available 24 hours after the event)
□ Access to the conference documentation
on the Document Portal
£499.00 + VAT £598.80
□ The Conference Presentations – paper copy 499.00 -
£
£499.00
(or only £300 if ordered with the Document Portal)
PAYMENT
Email:
Address (if different from above):
Payment must be made to SMi Group Ltd, and received before the event, by one of
the following methods quoting reference P-109 and the delegate’s name. Bookings
made within 7 days of the event require payment on booking, methods of payment
are below. Please indicate method of payment:
Town/City:
Post/Zip Code:
Country:
Direct Tel:
Direct Fax:
VENUE The Marriott Regents Park Hotel, 128 King Henry’s Rd, London NW3 3ST
□ Please contact me to book my hotel
Alternatively call us on +44 (0) 870 9090 711,
email: hotels@smi-online.co.uk or fax +44 (0) 870 9090 712
Terms and Conditions of Booking
Payment: If payment is not made at the time of booking, then an invoice will be issued and must
be paid immediately and prior to the start of the event. If payment has not been received then
credit card details will be requested and payment taken before entry to the event. Bookings within
7 days of event require payment on booking. Access to the Document Portal will not be given
until payment has been received.
Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another
delegate to take your place at any time prior to the start of the event. Two or more delegates may
not ‘share’ a place at an event. Please make separate bookings for each delegate.
Cancellation: If you wish to cancel your attendance at an event and you are unable to send
a substitute, then we will refund/credit 50% of the due fee less a £50 administration charge,
providing that cancellation is made in writing and received at least 28 days prior to the start of
the event. Regretfully cancellation after this time cannot be accepted. We will however provide
the conferences documentation via the Document Portal to any delegate who has paid but is
unable to attend for any reason. Due to the interactive nature of the Briefings we are not normally
able to provide documentation in these circumstances. We cannot accept cancellations of
orders placed for Documentation or the Document Portal as these are reproduced specifically to
order. If we have to cancel the event for any reason, then we will make a full refund immediately,
but disclaim any further liability.
Alterations: It may become necessary for us to make alterations to the content, speakers, timing,
venue or date of the event compared to the advertised programme.
Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection
Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about
other products and services. Unless you tick here □ we may also share your data with third parties
offering complementary products or services. If you have any queries or want to update any of
the data that we hold then please contact our Database Manager databasemanager@smionline.co.uk or visit our website www.smi-online.co.uk/updates quoting the URN as detailed above
your address on the attached letter.
□ UK BACS
□ Wire Transfer
□ Cheque
□ Credit Card
Sort Code 300009, Account 00936418
Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU
Swift (BIC): LOYDGB21013, Account 00936418
IBAN GB48 LOYD 3000 0900 9364 18
We can only accept Sterling cheques drawn on a UK bank.
□ Visa □ MasterCard □ American Express
All credit card payments will be subject to standard credit card charges.
□□□□ □□□□ □□□□ □□□□
Valid From □□/□□ Expiry Date □□/□□
CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card
Card No:
Cardholder’s Name:
Signature: Date:
I agree to be bound by SMi’s Terms and Conditions of Booking.
Card Billing Address (If different from above):
VAT
VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged on live
Streaming, on Demand, Document portal and literature distribution for all UK customers and for those
EU Customers not supplying a registration number for their own country here
If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email them at events@smi-online.co.uk